3 October 2017Americas

FDA issues new guidance to boost generic competition

The US Food and Drug Administration (FDA) has issued new guidance as part of its bid to target the barriers to generic drug competition.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

FDA targets barriers to generic competition

26 June 2017 The Food and Drug Administration has announced its intention to target the barriers to generic drug competition.

FDA to increase drug competition and speed up ANDA reviews

28 June 2017 The US Food and Drug Administration has revealed plans to increase competition in the US market for prescription drugs, as well as to facilitate the entry of generic drugs into the market.

FDA reveals further steps to encourage generic competition

3 January 2018 The US Food and Drug Administration revealed additional steps aimed at encouraging generic competition today.

More on this story

FDA targets barriers to generic competition

26 June 2017 The Food and Drug Administration has announced its intention to target the barriers to generic drug competition.

FDA to increase drug competition and speed up ANDA reviews

28 June 2017 The US Food and Drug Administration has revealed plans to increase competition in the US market for prescription drugs, as well as to facilitate the entry of generic drugs into the market.

FDA reveals further steps to encourage generic competition

3 January 2018 The US Food and Drug Administration revealed additional steps aimed at encouraging generic competition today.

More on this story

FDA targets barriers to generic competition

26 June 2017 The Food and Drug Administration has announced its intention to target the barriers to generic drug competition.

FDA to increase drug competition and speed up ANDA reviews

28 June 2017 The US Food and Drug Administration has revealed plans to increase competition in the US market for prescription drugs, as well as to facilitate the entry of generic drugs into the market.

FDA reveals further steps to encourage generic competition

3 January 2018 The US Food and Drug Administration revealed additional steps aimed at encouraging generic competition today.

More features

Fed Circ orders Teva to delist five patents from Orange Book

Sarepta wins $115M in patent dispute over muscular dystrophy drug

Novartis shields eye-drop patent at European Patent Office

CREATES Act unfairly tips the scales to generics

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York